Systemic lupus erythematosus: an expert insight into emerging therapy agents in preclinical and early clinical development

References

• Magro R. Biological therapies and their clinical impact in the treatment of systemic lupus erythematosus. Ther Adv Musculoskelet Dis. 2019;11:1759720X19874309.
   PubMed Web of Science ®Google Scholar
• Mu Q, Zhang H, Luo XM. SLE: another autoimmune disorder influenced by microbes and diet? Front Immunol. 2015;6:608.
   PubMed Web of Science ®Google Scholar
• Chowdhary VR. Broad concepts in management of systemic lupus erythematosus. Mayo Clin Proc. 2017;92(5):744–761.
   PubMed Web of Science ®Google Scholar
• Mikdashi J, Nived O. Measuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical research. Arthritis Res Ther. 2015;17:183.
   PubMed Web of Science ®Google Scholar
• Fortin PR, Abrahamowicz M, Ferland D, et al. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2008;59:1796–1804.
   PubMed Web of Science ®Google Scholar
• Tam LS, Li EK, Wong CK, et al. Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus. Lupus. 2004;13:601–604.
   PubMed Web of Science ®Google Scholar
• Ginzler EM, Wofsy D, Isenberg D, et al. Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis Rheum. 2010;62:211–221.
   PubMed Web of Science ®Google Scholar
• Pego-Reigosa JM, Cobo-Ibáñez T, Calvo-Alén J, et al. Efficacy and safety of nonbiologic immunosuppressants in the treatment of nonrenal systemic lupus erythematosus: a systematic review. Arthritis Care Res. 2013;65:1775–1785.
   PubMed Web of Science ®Google Scholar
• Tunnicliffe DJ, Singh-Grewal D, Kim S, et al. Diagnosis, monitoring, and treatment of systemic lupus erythematosus: A systematic review of clinical practice guidelines. Arthritis Care Res. 2015;67:1440–1452.
   PubMed Web of Science ®Google Scholar
• Fanouriakis A, Kostopoulou M, Alunno A, et al. update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;2019(78):736–745.
   Google Scholar
• Henderson LK, Masson P, Craig JC, et al. Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis Off J Natl Kidney Found. 2013;61:74–87.
   PubMed Web of Science ®Google Scholar
• Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71:1771–1782.
   PubMed Web of Science ®Google Scholar
• Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. 2012;64:797–808.
   PubMed Web of Science ®Google Scholar
• Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med. 2013;368:777.
   PubMed Web of Science ®Google Scholar
• Zandman-Goddard G, Krauthammer A, Levy Y, et al. Long-term therapy with intravenous immunoglobulin is beneficial in patients with autoimmune diseases. Clin Rev Allergy Immunol. 2012;42:247–255.
   PubMed Web of Science ®Google Scholar
• Zandman-Goddard G, Blank M, Shoenfeld Y. Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside. Lupus. 2009;18:884–888.
   PubMed Web of Science ®Google Scholar
• Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62:222–233.
   PubMed Web of Science ®Google Scholar
• Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64:1215–1226.
   PubMed Web of Science ®Google Scholar
• Reddy V, Dahal LN, Cragg MS, et al. Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer? Drug Discov Today. 2016;21:1330–1338.
   PubMed Web of Science ®Google Scholar
• Davis LS, Reimold AM. Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus. Rheumatol Oxf Engl. 2017;56:i100–13.
   PubMed Web of Science ®Google Scholar
• Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet Lond Engl. 2011;377:721–731.
   PubMed Web of Science ®Google Scholar
• Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:3918–3930.
   PubMed Web of Science ®Google Scholar
• Wise LM, Stohl W. The safety of belimumab for the treatment of systemic lupus erythematosus. Expert Opin Drug Saf. 2019;18:1133–1144.
   PubMed Web of Science ®Google Scholar
• Collins CE, Dall’Era M, Kan H, et al. Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA. Lupus Sci Med. 2016;3:e000118.
   PubMed Web of Science ®Google Scholar
• Touma Z, Sayani A, Pineau CA, et al. Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study. Rheumatol Int. 2017;37:865–873.
   PubMed Web of Science ®Google Scholar
• Zhang F, Bae SC, Bass D, et al. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann Rheum Dis. 2018;77:355–363.
   PubMed Web of Science ®Google Scholar
• Stohl W, Schwarting A, Okada M, et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol Hoboken NJ. 2017;69:1016–1027.
   PubMed Web of Science ®Google Scholar
• Aringer M, Leuchten N, Schneider M. Treat to Target in Systemic Lupus Erythematosus. Rheum Dis Clin North Am. 2019;45:537–548.
   PubMed Web of Science ®Google Scholar
• Fattah Z, Isenberg DA. Recent developments in the treatment of patients with systemic lupus erythematosus: focusing on biologic therapies. Expert Opin Biol Ther. 2014;14:311–326.
   PubMed Web of Science ®Google Scholar
• Kyttaris VC. Novel Treatments in Lupus. Curr Rheumatol Rep. 2017;19:10.
   PubMed Web of Science ®Google Scholar
• Paley MA, Strand V, Kim AHJ. From mechanism to therapies in systemic lupus erythematosus. Curr Opin Rheumatol. 2017;29:178–186.
   PubMed Web of Science ®Google Scholar
• Vivek LP, Joseph S, James BB. The effect of anti-CD40 ligand in immune thrombocytopenic purpura. Br J Haematol. 2008;141:545–548.
   PubMed Web of Science ®Google Scholar
• Shock A, Burkly L, Wakefield I, et al. CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study. Arthritis Res Ther. 2015;17:234.
   PubMed Web of Science ®Google Scholar
• Sullivan BA, Tsuji W, Kivitz A, et al. Inducible T-cell co-stimulator ligand (ICOSL) blockade leads to selective inhibition of anti-KLH IgG responses in subjects with systemic lupus erythematosus. Lupus Sci Med. 2016;3:e000146.
   PubMed Web of Science ®Google Scholar
• Tanoue T, Atarashi K, Honda K. Development and maintenance of intestinal regulatory T cells. Nat Rev Immunol. 2016;16:295–309.
   PubMed Web of Science ®Google Scholar
• Wiener A, Schippers A, Wagner N, et al. CXCR5 is critically involved in progression of lupus through regulation of B cell and double-negative T cell trafficking. Clin Exp Immunol. 2016;185:22–32.
   PubMed Web of Science ®Google Scholar
• Pickering MC, Ismajli M, Condon MB, et al. Eculizumab as rescue therapy in severe resistant lupus nephritis. Rheumatol Oxf Engl. 2015;54:2286–2288.
   PubMed Web of Science ®Google Scholar
• Erkan D, Aguiar CL, Andrade D, et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev. 2014;13:685–696.
   PubMed Web of Science ®Google Scholar
• Frémeaux-Bacchi V, Legendre CM. The emerging role of complement inhibitors in transplantation. Kidney Int. 2015;88:967–973.
   PubMed Web of Science ®Google Scholar
• Wallace DJ. The evolution of drug discovery in systemic lupus erythematosus. Nat Rev Rheumatol. 2015;11:616–620.
   PubMed Web of Science ®Google Scholar
• Stohl W. Future prospects in biologic therapy for systemic lupus erythematosus. Nat Rev Rheumatol. 2013;9:705–720.
   PubMed Web of Science ®Google Scholar
• Rönnblom L, Alm GV, Eloranta ML. The type I interferon system in the development of lupus. Semin Immunol. 2011;23:113–121.
   PubMed Web of Science ®Google Scholar
• Crow MK, Olferiev M, Kirou KA. Targeting of type I interferon in systemic autoimmune diseases. Transl Res J Lab Clin Med. 2015;165:296–305.
   Google Scholar
• Luo S, Wang Y, Zhao M, et al. The important roles of type I interferon and interferon-inducible genes in systemic lupus erythematosus. Int Immunopharmacol. 2016;40:542–549.
   PubMed Web of Science ®Google Scholar
• Furie R, Khamashta M, Merrill JT. Anifrolumab, an anti-interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol. 2017;69:376–386.
   PubMed Web of Science ®Google Scholar
• Furie RA, Morand EF, Bruce IN, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 2019;1:e208–19.
   Google Scholar
• Salmon JE, Niewold TB. A successful trial for lupus - how good is good enough? N Engl J Med. 2020;382:287–288.
   PubMed Web of Science ®Google Scholar
• Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382:211–221.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Takeuchi T, Okada M, et al. Safety and tolerability of anifrolumab, a monoclonal antibody targeting type I interferon receptor, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study. Mod Rheumatol. 2020;30:101–108.
   PubMed Web of Science ®Google Scholar
• Furie R, Nicholls K, Cheng TT, et al. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol Hoboken NJ. 2014;66:379–389.
   PubMed Web of Science ®Google Scholar
• Pimentel-Quiroz VR, Ugarte-Gil MF, Alarcón GS. Abatacept for the treatment of systemic lupus erythematosus. Expert Opin Investig Drugs. 2016;25:493–499.
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Furie RA, Tanaka Y, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Lond Engl. 2018;392:222–231.
   PubMed Web of Science ®Google Scholar
• Hermann V, Batalov A, Smakotina S, et al. First use of cenerimod, a selective S1P1 receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study. Lupus Sci Med. 2019;6:e000354.
   PubMed Web of Science ®Google Scholar
• Liu E, Perl A. Pathogenesis and treatment of autoimmune rheumatic diseases. Curr Opin Rheumatol. 2019;31:307–315.
   PubMed Web of Science ®Google Scholar
• Donnelly RP, Finlay DK. Glucose, glycolysis and lymphocyte responses. Mol Immunol. 2015;68:513–519.
   PubMed Web of Science ®Google Scholar
• Loftus RM, Finlay DK. Immunometabolism: cellular metabolism turns immune regulator. J Biol Chem. 2016;291:1–10.
   PubMed Web of Science ®Google Scholar
• Ho PC, Bihuniak JD, Macintyre AN, et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T Cell responses. Cell. 2015;162:1217–1228.
   PubMed Web of Science ®Google Scholar
• Ursini F, Russo E, Pellino G, et al. Metformin and autoimmunity: a “new deal” of an old drug. Front Immunol. 2018;9:1236.
   PubMed Web of Science ®Google Scholar
• Wilson J, Sproule TJ, Manandhar P, et al. AI-03 efficacy and safety of intermittent 2-deoxyglucose therapy in mouse models of lupus. Lupus Sci Med. 2018;5:A1–A81.
   Google Scholar
• Li W, Qu G, Choi S-C, et al. Targeting T cell activation and lupus autoimmune phenotypes by inhibiting glucose transporters. Front Immunol. 2019;10:833.
   PubMed Web of Science ®Google Scholar
• Navarro Quiroz E, Chavez-Estrada V, Macias-Ochoa K, et al. Epigenetic mechanisms and posttranslational modifications in systemic lupus erythematosus. Int J Mol Sci. 2019;20:5679.
   Web of Science ®Google Scholar
• Eichten SR, Schmitz RJ, Springer NM. Epigenetics: beyond chromatin modifications and complex genetic regulation. Plant Physiol. 2014;165:933–947.
   PubMed Web of Science ®Google Scholar
• Perl A. Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases. Nat Rev Rheumatol. 2016;12:169–182.
   PubMed Web of Science ®Google Scholar
• Zhang S, Readinger JA, DuBois W, et al. Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production. Blood. 2011;117:1228–1238.
   PubMed Web of Science ®Google Scholar
• Lai ZW, Borsuk R, Shadakshari A, et al. Mechanistic target of rapamycin activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus erythematosus. J Immunol Baltim Md. 1950;2013(191):2236–2246.
   Google Scholar
• Fernandez D, Bonilla E, Mirza N, et al. Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum. 2006;54:2983–2988.
   PubMed Web of Science ®Google Scholar
• Lai ZW, Kelly R, Winans T, et al. Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial. Lancet Lond Engl. 2018;391:1186–1196.
   PubMed Web of Science ®Google Scholar
• Yap DYH, Tang C, Chan GCW, et al. Longterm data on sirolimus treatment in patients with lupus nephritis. J Rheumatol. 2018;45:1663–1670.
   PubMed Web of Science ®Google Scholar
• Lai ZW, Hanczko R, Bonilla E, et al. N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2012;64:2937–2946.
   PubMed Web of Science ®Google Scholar
• Eriksson P, Wallin P, Sjöwall C. Clinical experience of sirolimus regarding efficacy and safety in systemic lupus erythematosus. Front Pharmacol. 2019;10:82.
   PubMed Web of Science ®Google Scholar
• Gomes AC, Bueno AA, de Souza RGM, et al. Gut microbiota, probiotics and diabetes. Nutr J. 2014 Jun;17(13):60.
   Google Scholar
• Mach T. Clinical usefulness of probiotics in inflammatory bowel diseases. J Physiol Pharmacol Off J Pol Physiol Soc. 2006 Nov;57(Suppl 9):23–33.
   PubMedGoogle Scholar
• Dall’Ara F, Cutolo M, Andreoli L, et al. Vitamin D and systemic lupus erythematous: a review of immunological and clinical aspects. Clin Exp Rheumatol. 2018;36:153–162.
   PubMed Web of Science ®Google Scholar
• Kleinmann JF, Tubach F, Le Guern V, et al. International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. Autoimmun Rev. 2017;16:650–657.
   PubMed Web of Science ®Google Scholar
• Chen L, Morris DL, Vyse TJ. Genetic advances in systemic lupus erythematosus: an update. Curr Opin Rheumatol. 2017;29:423–433.
   PubMed Web of Science ®Google Scholar
• González LA, Alarcón GS. The evolving concept of SLE comorbidities. Expert Rev Clin Immunol. 2017;13:753–768.
   PubMed Web of Science ®Google Scholar
• Lateef A, Petri M. Systemic Lupus Erythematosus and Pregnancy. Rheum Dis Clin North Am. 2017;43:215–226.
   PubMed Web of Science ®Google Scholar
• Namjou B, Kothari PH, Kelly JA, et al. Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort. Genes Immun. 2011;12:270–279.
   PubMed Web of Science ®Google Scholar
• McGlasson S, Wiseman S, Wardlaw J, et al. Neurological disease in lupus: toward a personalized medicine approach. Front Immunol. 2018;9:1146.
   PubMed Web of Science ®Google Scholar
• Trevisani VFM, Castro AA, Neves Neto JF, et al. Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD002265. https://www-cochranelibrary-com.wolfson-ez.medlcp.tau.ac.il/cdsr/doi/10.1002/14651858.CD002265.pub2/full
   Web of Science ®Google Scholar
• Mok CC, Lau CS, Wong RWS. Treatment of lupus psychosis with oral cyclophosphamide followed by azathioprine maintenance: an open-label study. Am J Med. 2003;115:59–62.
   PubMed Web of Science ®Google Scholar
• Tokunaga M, Saito K, Kawabata D, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis. 2007;66:470–475.
   PubMed Web of Science ®Google Scholar
• Banchereau R, Hong S, Cantarel B, et al. Personalized Immunomonitoring uncovers molecular networks that stratify lupus patients. Cell. 2016;165:551–565.
   PubMed Web of Science ®Google Scholar
• Klavdianou K, Lazarini A, Fanouriakis A. Targeted biologic therapy for systemic lupus erythematosus: emerging pathways and drug pipeline. BioDrugs Clin Immunother Biopharm Gene Ther. 2020;34:133–147.
   Google Scholar
• Deapen D, Escalante A, Weinrib L, et al. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum. 1992;35:311–318.
   PubMed Web of Science ®Google Scholar
• Teruel M, Alarcón-Riquelme ME. The genetic basis of systemic lupus erythematosus: what are the risk factors and what have we learned. J Autoimmun. 2016;74:161–175.
   PubMed Web of Science ®Google Scholar
• Patel DR, Richardson BC. Epigenetic mechanisms in lupus. Curr Opin Rheumatol. 2010;22:478–482.
   PubMed Web of Science ®Google Scholar
• Liu J, Berthier CC, Kahlenberg JM. Enhanced inflammasome activity in systemic lupus erythematosus is mediated via type I interferon-induced up-regulation of interferon regulatory factor 1. Arthritis Rheumatol Hoboken NJ. 2017;69:1840–1849.
   PubMed Web of Science ®Google Scholar
• Salloum R, Franek BS, Kariuki SN, et al. Genetic variation at the IRF7/PHRF1 locus is associated with autoantibody profile and serum interferon-alpha activity in lupus patients. Arthritis Rheum. 2010;62:553–561.
   PubMed Web of Science ®Google Scholar
• Perl A. Emerging new pathways of pathogenesis and targets for treatment in systemic lupus erythematosus and Sjogren’s syndrome. Curr Opin Rheumatol. 2009;21:443–447.
   PubMed Web of Science ®Google Scholar
• Alperin JM, Ortiz-Fernández L, Sawalha AH. Monogenic lupus: A developing paradigm of disease. Front Immunol. 2018;9:2496.
   PubMed Web of Science ®Google Scholar
• Ceccarelli F, Perricone C, Borgiani P, et al. Genetic factors in systemic lupus erythematosus: contribution to disease Phenotype. J Immunol Res. 2015;2015:745647.
   PubMed Web of Science ®Google Scholar
• Harley JB, Kelly JA, Kaufman KM. Unraveling the genetics of systemic lupus erythematosus. Springer Semin Immunopathol. 2006;28:119–130.
   PubMed Web of Science ®Google Scholar
• Niu Z, Zhang P, Tong Y. Value of HLA-DR genotype in systemic lupus erythematosus and lupus nephritis: a meta-analysis. Int J Rheum Dis. 2015;18:17–28.
   PubMed Web of Science ®Google Scholar
• Gaffney PM, Kearns GM, Shark KB, et al. A genome-wide search for susceptibility genes in human systemic lupus erythematosus sib-pair families. Proc Natl Acad Sci. 1998;95:14875–14879.
   PubMed Web of Science ®Google Scholar
• Hitotsumatsu O, Ahmad RC, Tavares R, et al. The ubiquitin-editing enzyme A20 restricts nucleotide-binding oligomerization domain containing 2-triggered signals. Immunity. 2008;28:381–390.
   PubMed Web of Science ®Google Scholar
• Bentham J, Morris DL, Graham DSC, et al. Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus. Nat Genet. 2015;47:1457–1464.
   PubMed Web of Science ®Google Scholar
• Morris DL, Sheng Y, Zhang Y, et al. Genome-wide association meta-analysis in Chinese and European individuals identifies ten new loci associated with systemic lupus erythematosus. Nat Genet. 2016;48:940–946.
   PubMed Web of Science ®Google Scholar
• Langefeld CD, Ainsworth HC, Cunninghame Graham DS, et al. Transancestral mapping and genetic load in systemic lupus erythematosus. Nat Commun. 2017;8:16021.
   PubMed Web of Science ®Google Scholar
• Lerang K, Gilboe IM, Gran JT. Differences between rheumatologists and other internists regarding diagnosis and treatment of systemic lupus erythematosus. Rheumatol Oxf Engl. 2012;51:663–669.
   PubMed Web of Science ®Google Scholar
• Costedoat-Chalumeau N, Pouchot J, Guettrot-Imbert G, et al. Adherence to treatment in systemic lupus erythematosus patients. Best Pract Res Clin Rheumatol. 2013;27:329–340.
   PubMed Web of Science ®Google Scholar
• Feldman CH, Costenbader KH, Solomon DH, et al. Area-level predictors of medication nonadherence among US medicaid beneficiaries with lupus: A multilevel study. Arthritis Care Res. 2019;71:903–913.
   Web of Science ®Google Scholar
• Prados-Moreno S, Sabio JM, Pérez-Mármol JM, et al. Adherence to treatment in patients with systemic lupus erythematosus. Med Clin (Barc). 2018;150:8–15.
   PubMed Web of Science ®Google Scholar
• Singh JA, Hossain A, Mudano AS, et al. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2017;5:CD012657.
   PubMedGoogle Scholar
• Emery P, Pope JE, Kruger K, et al. Efficacy of monotherapy with biologics and JAK inhibitors for the treatment of rheumatoid arthritis: A systematic review. Adv Ther. 2018;35:1535–1563.
   PubMed Web of Science ®Google Scholar
• Touma Z, Gladman DD. Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments. Lupus Sci Med. 2017;4:e000239.
   PubMed Web of Science ®Google Scholar
• Murphy G, Isenberg DA. New therapies for systemic lupus erythematosus — past imperfect, future tense. Nat Rev Rheumatol. 2019;15:403–412.
   PubMed Web of Science ®Google Scholar
• Van Vollenhoven R, Voskuyl A, Bertsias G, et al. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann Rheum Dis. 2017;76:554–561.
   PubMed Web of Science ®Google Scholar
• Merrill JT, Manzi S, Aranow C, et al. Lupus community panel proposals for optimising clinical trials: 2018. Lupus Sci Med. 2018;5:e000258.
   PubMed Web of Science ®Google Scholar
• Tocut M, Brenner R, Zandman-Goddard G. Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev. 2018;17:610–616.
   PubMed Web of Science ®Google Scholar
• Moulton VR, Suarez-Fueyo A, Meidan E, et al. Pathogenesis of human systemic lupus erythematosus: A cellular perspective. Trends Mol Med. 2017;23:615–635.
   PubMed Web of Science ®Google Scholar
• Sciascia S, Radin M, Roccatello D, et al. Recent advances in the management of systemic lupus erythematosus. F1000Res. 2018;7:F1000 Faculty Rev–970.
   Google Scholar
• Fanouriakis A, Bertsias G. Changing paradigms in the treatment of systemic lupus erythematosus. Lupus Sci Med. 2019;6:e000310.
   PubMed Web of Science ®Google Scholar
• Jones A, Muller P, Dore CJ, et al. Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial. BMJ Open. 2019;9:e032569.
   PubMedGoogle Scholar
• Iaccarino L, Bartoloni E, Carli L, et al. Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry. Clin Exp Rheumatol. 2015;33:449–456.
   PubMed Web of Science ®Google Scholar
• Ehrenstein MR, Wing C. The BAFFling effects of rituximab in lupus: danger ahead? Nat Rev Rheumatol. 2016;12:367–372.
   PubMed Web of Science ®Google Scholar
• Carter LM, Isenberg DA, Ehrenstein MR. Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. Arthritis Rheum. 2013;65:2672–2679.
   PubMed Web of Science ®Google Scholar
• Teng YKO, Bruce IN, Diamond B, et al. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol. BMJ Open. 2019;9:e025687.
   PubMed Web of Science ®Google Scholar
• Van Dam LS, Osmani Z, Kamerling SWA, et al. A reverse translational study on the effect of rituximab, rituximab plus belimumab, or bortezomib on the humoral autoimmune response in SLE. Rheumatology. 2018;48:1573–1579.
   Google Scholar
• Ahmed AR, Kaveri S. Reversing autoimmunity combination of rituximab and intravenous immunoglobulin. Front Immunol. 2018;9:1189.
   PubMed Web of Science ®Google Scholar
• Toro-Domínguez D, Lopez-Domínguez R, García Moreno A, et al. Differential treatments based on drug-induced gene expression signatures and longitudinal systemic lupus erythematosus stratification. Sci Rep. 2019;9:15502.
   PubMed Web of Science ®Google Scholar
• Toro‐Domínguez D, Martorell‐Marugán J, Goldman D, et al. Stratification of systemic lupus erythematosus patients into three groups of disease activity progression according to longitudinal gene expression. Arthritis Rheumatol. 2018;70:2025–2035.
   PubMed Web of Science ®Google Scholar
• Zollars E, Courtney SM, Wolf BJ, et al. Clinical application of a modular genomics technique in systemic lupus erythematosus: progress towards precision medicine. Int J Genomics. 2016;2016:7862962.
   PubMed Web of Science ®Google Scholar
• Panousis NI, Bertsias GK, Ongen H, et al. Combined genetic and transcriptome analysis of patients with SLE: distinct, targetable signatures for susceptibility and severity. Ann Rheum Dis. 2019;78:1079–1089.
   PubMed Web of Science ®Google Scholar